The estimated Net Worth of Steve Gorlin is at least $14.7 Million dollars as of 9 November 2023. Mr. Gorlin owns over 75,680 units of BioVie stock worth over $133,975 and over the last 12 years he sold BIVI stock worth over $14,517,531. In addition, he makes $0 as Director at BioVie.
Sign up
Mr. Gorlin BIVI stock SEC Form 4 insiders trading
Steven has made over 40 trades of the BioVie stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 75,680 units of BIVI stock worth $127,899 on 9 November 2023.
The largest trade he's ever made was buying 571,429 units of BioVie stock on 1 December 2016 worth over $1,000,001. On average, Steven trades about 83,299 units every 79 days since 2012. As of 9 November 2023 he still owns at least 46,358 units of BioVie stock.
You can see the complete history of Mr. Gorlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steven Gorlin biography
Steven Gorlin serves as Director of the Company. Mr. Steve Gorlin has founded many biotechnology and pharmaceutical companies over the past forty-five years, including Hycor Biomedical, Inc. (acquired by Agilent), Theragenics Corporation (NYSE: TGX), Medicis Pharmaceutical Corporation (sold to Valeant for approximately $2.6 billion), EntreMed, Inc. (NASDAQ: ENMD), MRI Interventions (MRIC), DARA BioSciences, Inc. (NASDAQ: DARA), MiMedx (NASDAQ: MDXG), Medivation, Inc. (NASDAQ: MDVN), sold to Pfizer for $14 billion and Conkwest which became NantKwest (NASDAQ: NK). Mr. Gorlin served for many years on the Business Advisory Council to the Johns Hopkins School of Medicine and on The Johns Hopkins BioMedical Engineering Advisory Board. He also served on the Board of the Andrews Institute. He is currently a member of the Research Institute Advisory Committee (RIAC) of Massachusetts General Hospital. He started The Touch Foundation, a nonprofit organization for the blind and was a principal financial contributor to the founding of Camp Kudzu for diabetic children.
How old is Steven Gorlin?
Steven Gorlin is 82, he's been the Director of BioVie since 2020. There are no older and 10 younger executives at BioVie.
What's Steven Gorlin's mailing address?
Steve's mailing address filed with the SEC is C/O BIOVIE INC., 680 W NYE LANE STE 201, CARSON CITY, NV, 89703.
Insiders trading at BioVie
Over the last 9 years, insiders at BioVie have traded over $352,740 worth of BioVie stock and bought 67,100 units worth $464,015 . The most active insiders traders include Terren S Peizer, Steve Gorlin und Richard J Berman. On average, BioVie executives and independent directors trade stock every 122 days with the average trade being worth of $301,811. The most recent stock trade was executed by Cuong V Do on 4 March 2024, trading 10,000 units of BIVI stock currently worth $28,900.
What does BioVie do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
What does BioVie's logo look like?
Complete history of Mr. Gorlin stock trades at MiMedx Inc, NantKwest Inc, PolarityTE Inc und BioVie
BioVie executives and stock owners
BioVie executives and other stock owners filed with the SEC include:
-
Jonathan M. Adams M.B.A., MBA,
Exec. VP of Liver Disease Program -
Joanne Wendy Kim CPA,
CFO & Corp. Sec. -
Cuong Viet Do M.B.A., MBA,
Pres, CEO & Director -
Mina Sooch,
Independent Director -
Michael Sherman,
Independent Director -
James Lang,
Independent Director -
Hari Kumar,
Independent Director -
Sigmund Rogich,
Director -
Rajah Menon,
Director -
Robert Hariri,
Director -
Steven Gorlin,
Director -
Richard Berman,
Director -
Patrick Yeramian,
Chief Medical Officer -
Penelope Markham,
Chief Scientific Officer -
J. Wendy Kim,
Chief Financial Officer, Corporate Secretary -
Terren Peizer,
Chief Executive Officer, Director -
Jonathan Adams,
President, Chief Operating Officer -
Dr. Joseph M. Palumbo M.D.,
Chief Medical Officer -
Clarence N. Ahlem,
Exec. VP of Neuroscience Product Devel. -
Dr. Christopher L. Reading Ph.D.,
Exec. VP of Neuroscience R&D -
Denise Smith,
Sr. VP of Manufacturing & Devel. -
Dr. Penelope Markham Ph.D.,
Exec. VP of Liver Disease R&D -
R Richard Wieland,
interim CFO -
Julie G Anderson,
Director -
Cuong V Do,
President & CEO -
Steve Gorlin,
Director -
Clarence N. Ahlem,
EVP Neuroscience Product Dev. -
Christopher Reading,
EVP Neuroscience R&D -
Joseph M Palumbo,
Chief Medical Officer